Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ.

Thromb Haemost. 2010 Feb;103(2):360-71. doi: 10.1160/TH09-08-0579. Epub 2009 Dec 18.

PMID:
20024501
2.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ.

Clin Ther. 2009 Jan;31(1):194-212. doi: 10.1016/j.clinthera.2009.01.001.

PMID:
19243718
3.
4.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Review.

5.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Pharmacoeconomics. 2012 Feb 1;30(2):137-46. doi: 10.2165/11591590-000000000-00000. Review.

PMID:
22185183
6.

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI.

Thromb Haemost. 2009 Jan;101(1):77-85.

PMID:
19132192
7.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
8.

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group.

Lancet. 2007 Sep 15;370(9591):949-56. Erratum in: Lancet. 2007 Dec 15;370(9604):2004.

PMID:
17869635
9.

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P; BISTRO II Study Group.

J Thromb Haemost. 2005 Jan;3(1):103-11.

10.

Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.

Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, Vargas-Castrillón E.

Pharmacoeconomics. 2014 Sep;32(9):919-36. doi: 10.1007/s40273-014-0175-5.

PMID:
24895235
11.

[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].

Gómez Arrayas I, Suárez Fernández C, Gómez Cerezo JF, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C.

Rev Esp Salud Publica. 2012 Dec;86(6):601-12. doi: 10.4321/S1135-57272012000600006. Spanish.

12.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

13.

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.

Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N.

J Med Econ. 2011;14(2):238-44. doi: 10.3111/13696998.2011.564699. Epub 2011 Mar 9.

PMID:
21385145
14.

Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.

Postma MJ, Kappelhoff BS, van Hulst M, Brouwers JR.

J Med Econ. 2012;15(5):878-86. doi: 10.3111/13696998.2012.691144. Epub 2012 Jun 7.

PMID:
22563715
15.

Dabigatran etexilate for prevention of venous thromboembolism.

Eikelboom JE, Weitz JI.

Thromb Haemost. 2009 Jan;101(1):2-4. No abstract available.

PMID:
19132179
16.

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.

Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M.

Thromb Haemost. 2013 Nov;110(5):987-94. doi: 10.1160/TH12-12-0919. Epub 2013 Aug 22.

PMID:
23965805
17.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
18.

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.

Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees.

Thromb Res. 2010 Sep;126(3):175-82. doi: 10.1016/j.thromres.2010.03.021. Epub 2010 May 15.

PMID:
20434759
19.

[Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].

Omel'ianovskiĭ VV, Zagorodniĭ NV, Margieva AV, Tsfasman FM.

Khirurgiia (Mosk). 2010;(5):72-81. Russian. No abstract available.

PMID:
20568660
20.

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR; RE-MODEL Study Group.

J Thromb Haemost. 2007 Nov;5(11):2178-85.

Supplemental Content

Support Center